Captrust Financial Advisors bought a new position in Allergan (NYSE:AGN) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 1,067 shares of the company’s stock, valued at approximately $175,000.
Several other hedge funds and other institutional investors have also made changes to their positions in AGN. Edgewood Management LLC grew its position in shares of Allergan by 24.3% during the 3rd quarter. Edgewood Management LLC now owns 4,445,924 shares of the company’s stock valued at $911,192,000 after purchasing an additional 869,248 shares in the last quarter. Geode Capital Management LLC boosted its position in Allergan by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 3,422,365 shares of the company’s stock valued at $558,625,000 after buying an additional 72,303 shares during the period. Baupost Group LLC MA boosted its position in Allergan by 21.9% during the third quarter. Baupost Group LLC MA now owns 2,964,203 shares of the company’s stock valued at $607,513,000 after buying an additional 531,600 shares during the period. Parnassus Investments CA boosted its position in Allergan by 20.4% during the fourth quarter. Parnassus Investments CA now owns 2,161,833 shares of the company’s stock valued at $353,633,000 after buying an additional 365,914 shares during the period. Finally, Epoch Investment Partners Inc. boosted its position in Allergan by 1.0% during the third quarter. Epoch Investment Partners Inc. now owns 1,805,608 shares of the company’s stock valued at $370,060,000 after buying an additional 17,068 shares during the period. Hedge funds and other institutional investors own 77.97% of the company’s stock.
Shares of NYSE AGN traded down $3.61 during trading hours on Friday, hitting $161.52. 2,105,830 shares of the stock were exchanged, compared to its average volume of 2,920,951. The company has a quick ratio of 1.06, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The firm has a market cap of $56,263.71, a PE ratio of 9.88, a price-to-earnings-growth ratio of 1.15 and a beta of 1.18. Allergan has a 12 month low of $142.81 and a 12 month high of $256.80.
Allergan (NYSE:AGN) last released its earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, topping the consensus estimate of $4.74 by $0.12. The company had revenue of $4.33 billion for the quarter, compared to the consensus estimate of $4.28 billion. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. Allergan’s revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.90 EPS. equities research analysts anticipate that Allergan will post 15.58 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th were issued a $0.72 dividend. This is an increase from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 annualized dividend and a dividend yield of 1.78%. The ex-dividend date was Tuesday, February 27th. Allergan’s dividend payout ratio is 17.61%.
Several equities analysts have recently commented on AGN shares. Cantor Fitzgerald set a $191.00 price objective on shares of Allergan and gave the company a “hold” rating in a research note on Tuesday, December 12th. Credit Suisse Group set a $214.00 price target on shares of Allergan and gave the stock a “buy” rating in a research note on Tuesday, December 19th. They noted that the move was a valuation call. ValuEngine downgraded shares of Allergan from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Zacks Investment Research downgraded shares of Allergan from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Finally, Royal Bank of Canada set a $218.00 target price on shares of Allergan and gave the company a “buy” rating in a research note on Thursday, January 4th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $224.02.
In other news, CFO Matthew M. Walsh purchased 2,000 shares of the stock in a transaction that occurred on Wednesday, February 21st. The shares were purchased at an average cost of $160.94 per share, with a total value of $321,880.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Meury sold 58,879 shares of the company’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $160.62, for a total transaction of $9,457,144.98. The disclosure for this sale can be found here. Insiders bought a total of 8,095 shares of company stock worth $1,258,081 over the last ninety days. Insiders own 0.36% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/08/captrust-financial-advisors-invests-175000-in-allergan-plc-agn.html.
Allergan Company Profile
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.